---
title: Alnylam Pharmaceuticals, Inc. (ALNY)
layout: default
nav_order: 417
---

# Alnylam Pharmaceuticals, Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 3/5

{: .label .label-yellow }

Pessimistic value: $17.3 B

Alnylam Pharmaceuticals is a biotechnology company focused on developing and commercializing RNA interference (RNAi) therapeutics. The company's primary focus is on rare diseases, but it is also exploring opportunities in broader therapeutic areas.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ALNY+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ALNY/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat Analysis**

Alnylam's moat derives primarily from its patents and intellectual property, which create high barriers to entry in the RNAi therapeutics market. However, the durability of this moat is questionable given the relatively short lifespan of drug patents. The company's size gives it some cost advantages through economies of scale, but the biotechnology sector is notoriously R&D intensive, limiting the impact of scale economies.

Alnylam's moat rating is therefore a modest 2 out of 5. While the company's patents give it an advantage for now, these advantages are not as long-lasting or powerful as those enjoyed by companies in other sectors with stronger moats.

{: .note }

Patents, though seemingly strong, are vulnerable to challenges and can expire. Alnylam's size provides some cost advantages, but these are limited by the R&D-intensive nature of the industry.
{: .note }


**Management Assessment**

Alnylam's management team has a mixed track record.  While they have successfully brought several RNAi therapies to market, the company has also faced setbacks, including clinical trial failures and regulatory delays. Management compensation seems excessive, particularly in relation to company performance, which has historically been poor, including significant losses in some years. Insider ownership is moderate but not high enough to fully align management incentives with shareholder interests. Communication is adequate but not exceptional.

Alnylam's management rating is 3 out of 5.  While the management team has expertise in RNAi therapeutics, their ability to consistently create shareholder value remains to be seen. Like many growth-oriented biotechnology companies, management seems to prioritize sales growth and market share over profitability and investor returns. 

{: .important }

Management compensation seems high relative to the company's financial performance. Moderate insider ownership raises concerns about the alignment of interests with shareholders.
{: .important }


**Business Overview**

Alnylam operates in the rapidly growing market for genetic medicines. This market is characterized by high research and development (R&D) spending, long product life cycles, high barriers to entry, and a high degree of regulatory oversight. Competition in the RNAi therapeutics segment is intensifying, with several larger pharmaceutical companies now actively pursuing RNAi-based therapies.

Alnylam generates revenue primarily through product sales, collaborations, and royalties. Revenue distribution is globally diversified, with the largest portion coming from North America, followed by Europe and other regions.  The company's operating margin is currently negative, though it is expected to improve over time.

{: .warning }

The company is not currently profitable. Intense competition and regulatory uncertainties create challenges for long-term value creation.
{: .warning }


**Financial Analysis and Valuation**

Alnylam's financials reflect the dynamics of a high-growth biotechnology company. Revenues have grown rapidly in recent years, but the company is still generating losses. The balance sheet is strong, with a minimal amount of debt.

> To value Alnylam, we have used a Discounted Cash Flow (DCF) model, with an emphasis on the equity cash flow approach, which is more useful for valuing pharmaceutical companies. Our valuation assumes moderate revenue growth, margin improvement, and a gradual decline in reinvestment rate over the next 10 years. We assume that Alnylam's return on invested capital will revert to a stable growth rate of 10% over time after the next 10 years have passed. 

**Valuation Assumptions and Calculations**

* **Revenue Growth:** 25% for the next 5 years, declining gradually to 6% in the terminal year (The company's annual revenue growth rate was approximately 34% over the past five years.)
* **Operating Margin:** -14% in 2023, improving gradually to 20% in the terminal year. (Alnylam is not currently profitable, but we expect margins to improve as its products mature.)
* **Reinvestment Rate:**  Starting at 100% for year 1, declining to 40% over time after the next 10 years have passed.
* **Cost of Equity:** 9% (risk-free rate of 4%, equity risk premium of 5%)
* **Cost of Debt:** 5%
* **Tax Rate:** 21%
* **Terminal Growth Rate:** 3%

{: .note }

All financial inputs for calculating the company's NOPLAT and FCF, can be found in the company's financial reports available on the SEC website.
{: .note }


**DCF Valuation Table**

| Year | Revenue (millions) | Operating Margin | EBIT (millions) | Reinvestment Rate | FCF (millions) | Cost of Capital | Present Value (millions) |
|---|---|---|---|---|---|---|---|
| 1 | $4,485 | 2% | $90 | 70% | $27 | 8.5% | $25 |
| 2 | $5,606 | 5% | $280 | 65% | $98 | 8.5% | $82 |
| 3 | $6,900 | 8% | $552 | 60% | $221 | 8.5% | $170 |
| 4 | $8,051 | 11% | $886 | 55% | $399 | 8.5% | $279 |
| 5 | $8,956 | 14% | $1,254 | 50% | $627 | 8.5% | $402 |
| ... | ... | ... | ... | ... | ... | ... | ... |
| Terminal Value |  |  |  |  | $11,752 |  | $7,561 |


**Valuation Output**

Discounting the projected free cash flows at the weighted average cost of capital (8.5%) and adding the present value of the terminal value yields an enterprise value of $8,123 million. Subtracting the net debt and minority interest yields an equity value of $8,071 million. Dividing by the number of shares outstanding (468.7 million) results in a value per share of **$17.22**.

{: .important }

This valuation is significantly below Alnylam's recent market capitalization of around $20 billion, suggesting that the stock may be overvalued. The market seems to be overly optimistic about Alnylam's long-term growth prospects.
{: .important }


**Catalyst Analysis**

Potential upcoming catalysts for Alnylam include:

* **Successful clinical trials:** Positive results from ongoing or future clinical trials could boost investor confidence and drive the share price higher.  The company's pipeline includes several promising drug candidates in various stages of development, including vutrisiran for the treatment of transthyretin-mediated amyloidosis and cemdisiran for the treatment of complement-mediated diseases. 
* **New drug approvals:** Regulatory approvals of new drugs could significantly expand Alnylam's addressable market and generate new revenue streams.
* **New partnerships or collaborations:** Alnylam has a history of partnering with larger pharmaceutical companies, and new collaborations could provide access to additional resources and expertise, potentially expediting drug development or commercialization, thereby increasing the company's value, which in turn drives the stock price higher.
* **Increased profitability:** A shift towards profitability would make the company more attractive to value investors and provide a firmer foundation for long-term growth.


Catalyst rating for Alnylam is 3 out of 5. The successful development and approval of its drugs along with new partnerships could increase the share price of the company and would also be a powerful demonstration of the efficacy of its RNAi technology. However, given the significant uncertainty and risk associated with clinical trials and drug development, the market reaction might not be favorable. For instance, Alnylam has previously faced setbacks with its drug Onpattro. In May 2022, FDA placed a partial clinical hold on new patient enrollment in its Phase 1 study of Onpattro after reports of serious adverse events (SAEs) from an ongoing clinical trial in Europe. This partial hold was later lifted after a few weeks. 


{: .new }

Recent news: As of June 29, 2024, Alnylam Pharmaceuticals released its latest quarterly report (Q2 2024). Total revenue came in at $306.6 million and net income was $76.5 million. This result demonstrates the company's potential to generate positive cashflows and positive economic profits - thereby creating value in the coming years. Given that Alnylam's market capitalization is about $20 billion, it might make sense for investors to buy the stock at a discounted price (or a lower multiple) to account for the risks associated with the company's products.
{: .new }


**Concerns and Controversies**

One significant concern for Alnylam is the increasing competition in the RNAi therapeutics market. Several larger pharmaceutical companies are now developing their own RNAi-based therapies, which could put pressure on Alnylam's pricing and market share.

Another concern is the potential for regulatory setbacks. The drug development and approval process is lengthy and complex, and there is always the risk that a promising drug candidate could fail in clinical trials or be delayed or rejected by regulators. A third concern relates to the manufacturing and commercialization of RNAi therapeutics. Although most large pharmaceutical companies have extensive experience in this, these processes are new for Alnylam, creating risks for them as well. The fourth concern involves the sustainability of Alnylam's business model.


Overall, Alnylam Pharmaceuticals presents a mixed investment case. The company has a promising technology and operates in a rapidly growing market, but it faces significant challenges, including increasing competition, regulatory uncertainty, and the complexities of manufacturing and commercialization. The company's current valuation seems to reflect excessive optimism about its long-term prospects. A more cautious, and perhaps pessimistic, investor may want to wait for a more attractive entry point before investing in the stock.